^
Association details:
Biomarker:No biomarker
Cancer:Thymoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
The NCCN panel does not recommend pembrolizumab in patients with thymomas because of concerns about immune-related events...